CLINICAL TRIALS PROFILE FOR FETZIMA

All Clinical Trials for FETZIMA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02265367 ↗	Novel Medication as a Potential Smoking Cessation Aid	Completed	University of Minnesota	Early Phase 1	2015-01-01	The purpose of this study is to provide preliminary information assessing if levomilnacipran may be effective at increasing smoking cessation rates.
NCT02265367 ↗	Novel Medication as a Potential Smoking Cessation Aid	Completed	University of Minnesota - Clinical and Translational Science Institute	Early Phase 1	2015-01-01	The purpose of this study is to provide preliminary information assessing if levomilnacipran may be effective at increasing smoking cessation rates.
NCT02288325 ↗	A Multicenter, Relapse Prevention Study With Levomilnacipran Extended Release (ER) in Participants With Major Depressive Disorder	Completed	Forest Laboratories	Phase 4	2014-11-18	This study evaluates the efficacy, safety and tolerability of levomilnacipran extended-release (ER) compared with placebo in the prevention of depression relapse in major depressive disorder (MDD).
NCT02431806 ↗	Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive Disorder	Completed	Forest Laboratories	Phase 3	2015-06-23	The purpose of this study is to evaluate the efficacy, safety, and tolerability of levomilnacipran ER relative to placebo in adolescent outpatients (12-17 years) with Major Depressive Disorder (MDD). In addition, the study is designed to obtain pharmacokinetics (PK) data to guide dose selection for future pediatric studies of levomilnacipran.
NCT02466958 ↗	Trial of Levomilnacipran in Geriatric Depression	Completed	University of California, Los Angeles	Phase 4	2016-06-01	The purpose of this study is to examine the effects of levomilnacipran (FETZIMA) compared to placebo for the treatment of depression in older adults.
NCT02720198 ↗	Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDD	Completed	Forest Laboratories	Phase 3	2017-01-23	This study's primary objective is to compare the efficacy and tolerability of switching patients with inadequate relief on generic SSRIs to levomilnacipran versus adding a new treatment (quetiapine) to the participants' existing treatment with people diagnosed with depression (major depression disorder). The secondary objective is to examine the response and remission rates following the switch from a generic SSRI to levomilnacipran ER and augmentation with quetiapine along with examining changes in neurocognitive and apathy measures after the switch.

Clinical Trial Conditions for FETZIMA

Condition Name

Condition Name for FETZIMA
Intervention	Trials
Major Depressive Disorder	4
None (i.e. Healthy Volunteers)	1
Tobacco Use Disorder	1
Depressive Disorder, Major	1

Condition MeSH

Condition MeSH for FETZIMA
Intervention	Trials
Depression	5
Depressive Disorder, Major	5
Depressive Disorder	5
Disease	2

Clinical Trial Locations for FETZIMA

Trials by Country

Trials by Country for FETZIMA
Location	Trials
United States	50
Canada	1
Puerto Rico	1

Trials by US State

Trials by US State for FETZIMA
Location	Trials
Georgia	3
California	3
Illinois	2
Florida	2
Connecticut	2

Clinical Trial Progress for FETZIMA

Clinical Trial Phase

Clinical Trial Phase for FETZIMA
Clinical Trial Phase	Trials
Phase 4	4
Phase 3	2
Early Phase 1	1

Clinical Trial Status

Clinical Trial Status for FETZIMA
Clinical Trial Phase	Trials
Completed	5
Recruiting	1
Active, not recruiting	1

Clinical Trial Sponsors for FETZIMA

Sponsor Name

Sponsor Name for FETZIMA
Sponsor	Trials
Forest Laboratories	3
University of Pittsburgh	1
Allergan	1

Sponsor Type

Sponsor Type for FETZIMA
Sponsor	Trials
Other	9
Industry	4
NIH	1